News | July 31, 2007

New Technology May Lead to Earlier Cancer Detection

August 1, 2007 - The results of a pilot study on a new optical technology, coupled with routine endoscopy, presented in the Aug. 1 issue of Clinical Cancer Research, could represent a new approach to detecting pancreatic cancer at a very early stage.

Developed by Northwestern University biomedical engineers, the new optical technology, with routine endoscopy, exposes cellular changes indicative of cancer in tissue near the pancreas that had previously been detectable only through intensive radiologic scanning or invasive surgery.

“Pancreatic cancer is not often detected early because it is a rather inaccessible organ, so this technique holds the potential to be the first reliable, routine screening tool for pancreatic cancer,” said co-author author Randall Brand, M.D., an associate professor of medicine at Northwestern University and clinician at Evanston Northwestern Healthcare. “If we could apply this to those at high risk – such as people with chronic pancreatitis or who have a family history of pancreatic cancer– we might see a drastic improvement in pancreatic cancer survival.”

The optical technology used to detect the field effect of pancreatic cancer was developed by the senior author of the study Vadim Backman, Ph.D., a professor of biomedical engineering at Northwestern along with his graduate student, Yang Liu, Ph.D, the first author on the report. With a single instrument, Backman can use two different means of detecting the optical properties of a tissue sample, both of which were developed in his laboratory: four-dimensional elastic light scattering fingerprinting (4D-ELF) and low-coherence enhanced backscattering spectroscopy (LEBS).

“We are able to use the optical properties of a cell’s structure to serve as a marker for disease,” said Backman. “These are changes within the tissue that cannot be detected through any other means. Neither antibodies nor diagnostic assays can detect them.”

According to Backman, optical markers are independent of other factors within the tissue microenvironment. “The markers do not change if the patient is a smoker. And the markers do not change with the location, stage or size of the tumor in the pancreas,” he said.

Researchers are currently involved in a larger study of the technique and its refinement. They estimate that the technology may be put into practice within three years.

The study was supported by funding from the National Science Foundation and the National Institutes of Health.

For more information: www.aacr.org

Related Content

Florida Hospital First in State to Adopt NeuroLogica's BodyTom Elite CT
News | Computed Tomography (CT) | June 14, 2018
June 14, 2018 — NeuroLogica, a subsidiary of Samsung Electronics Co.
Raysearch RayStation
Feature | Radiation Therapy | June 05, 2018 | By Melinda Taschetta-Millane
Treatment planning systems are at the heart of r...
News | Treatment Planning | May 24, 2018
Daniela Schmitt, Ph.D., took top honors in the overall category of the 2018 TROG Plan Study: Stereotactic Radiosurgery...
News | Computed Tomography (CT) | May 21, 2018
The Istituto Oncologico Veneto (IOV) in Padua, Italy, has acquired MILabs’ latest-generation Versatile Emission...
RayStation Users Win Inaugural Treatment Planning World Championships
News | Treatment Planning | April 27, 2018
In the first World Championships of Treatment Planning, arranged by radiation oncology analytics company ProKnow and...
Brainlab Introduces New Hi-Res Planning Algorithm for VersaHD
News | Treatment Planning | April 24, 2018
Brainlab announced the implementation of a software solution that can achieve better radiation dose conformity around...
Varian Launches Velocity 4.0 Cancer Imaging Software
Technology | Treatment Planning | April 16, 2018
April 16, 2018 — Varian announced a new version of its Velocity cancer imaging software that includes Rapidsphere, a
MD Anderson and RaySearch Partner to Advance Adaptive Radiation Therapy
News | Treatment Planning | February 26, 2018
The University of Texas MD Anderson Cancer Center and RaySearch Laboratories announced a new strategic alliance with...
Mirada Medical Releases DLCExpert for Radiotherapy Treatment Planning
Technology | Treatment Planning | February 22, 2018
February 22, 2018 — U.K.-based medical imaging software provider Mirada Medical has released DLCExpert, the first com
Mitchell Cancer Institute Selects RayStation for TomoTherapy Planning
News | Treatment Planning | February 16, 2018
The University of South Alabama Mitchell Cancer Institute (MCI) in Mobile, Ala., has selected RayStation as its...
Overlay Init